ReviewJournal of cellular and molecular medicine2025
Innate Lymphoid Cells Are the Rheostat of Immune Response in the Kidney.
Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IFN-γ-dominant immune shift is associated with reduced protective ILC2 responses in chronic kidney disease.Frontiers in immunology · 2026Article
- Innate Lymphoid Cells Are the Rheostat of Immune Response in the Kidney.Journal of cellular and molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Kidney disease ranks as the seventh most significant and the third fastest-growing risk factor contributing to mortality globally. Innate lymphoid cells (ILCs) are tissue-resident immune cells that lack antigen-specific receptors and produce robust cytokines. ILCs play vital roles in infection, allergy, metabolic disorders, cancers, and tissue homeostasis. Recent studies have found that ILCs are manipulated for various kidney diseases. ILCs are classified into natural killer (NK) cells, ILC1s, ILC2s, ILC3s, and regulatory ILCs (ILCregs). We mainly discuss ILC1s, ILC2s, and ILC3s in kidney diseases. ILC2s and ILC3s are distributed along the renal vessels, and ILC3s are involved in the formation of ectopic lymphoid structures. ILCs secrete a variety of active cytokines, which can directly act on renal parenchymal cells or recruit other immune cells to affect kidney disease. Both acute kidney injury (AKI) and chronic kidney disease (CKD) are regulated by ILCs. ILC2s play a protective role in AKI and glomerulonephritis. Though ILC3s promote fibrosis in CKD, the roles of ILC2s in kidney fibrosis remain controversial. ILC1s and ILC3s promote glomerulonephritis. Kidney diseases will benefit from further studies focusing on the epigenetic/metabolic/neuron modulation and plasticity of ILCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.